Expand PRLD Menu
PRLD MENU

PRLD Latest Press Releases

-- December 16, 2025 --

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards Globe Newswire 12:18 PM

-- December 6, 2025 --

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs Globe Newswire 11:00 AM

-- November 26, 2025 --

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm Globe Newswire 11:10 AM

-- November 20, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD PRNewswire 10:00 AM

-- November 19, 2025 --

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm Globe Newswire 10:40 AM
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B Globe Newswire 9:45 AM

-- November 12, 2025 --

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Globe Newswire 7:01 AM

-- November 11, 2025 --

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm Business Wire 11:24 PM

-- November 4, 2025 --

Prelude Therapeutics Announces Strategic Business Update Globe Newswire 7:05 AM
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors Globe Newswire 7:01 AM

-- November 3, 2025 --

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting Globe Newswire 9:01 AM

-- October 17, 2025 --

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors Globe Newswire 7:30 AM

-- August 14, 2025 --

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes